A Meta-analysis of Clinical Trials Evaluating the Impact of Bivalirudin-based Anticoagulation for Primary Percutaneous Coronary on Long-Term Mortality-Reference-Cited by-同舟云学术

A Meta-analysis of Clinical Trials Evaluating the Impact of Bivalirudin-based Anticoagulation for Primary Percutaneous Coronary on Long-Term Mortality

Published:2021-07 Issue:1 Volume:78 Page:e40-e44
ISSN:0160-2446
Container-title:Journal of Cardiovascular Pharmacology
language:en
Short-container-title:

Author:

Jagadish Pooja S.,Le Francis K.,Labroo Ajay,Nasr Abrar,Rashid Abdul,Khan Babar,Shah Rahman

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Pharmacology

Reference26 articles.

1. 2018 ESC/EACTS guidelines on myocardial revascularization;Neumann;Eur Heart J.,2019

2. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines;O'Gara;J Am Coll Cardiol.,2013

3. An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention;Shah;Am Heart J.,2016

4. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial;Han;JAMA,2015

5. Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial;Zeymer;Eur Heart J.,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential Use of Glycoprotein IIb/IIIa Inhibitors with Bivalirudin in Patients with STEMI Undergoing PCI: A Systematic Review and Meta-Analysis;American Journal of Cardiovascular Drugs;2024-04-29

2. One-Year Safety and Effectiveness of Bivalirudin versus Heparin in Patients Undergoing Elective Percutaneous Coronary Intervention;Reviews in Cardiovascular Medicine;2023-07-31

3. Bivalirudin Use for Primary Percutaneous Coronary Intervention on Long-Term Mortality;Journal of Cardiovascular Pharmacology;2021-07

4. Practicability of Bivalirudin plus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis;Clinical and Applied Thrombosis/Hemostasis;2021-01